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Synthesis and growth-inhibitory activities of imidazo[5,1-d]-1,2,3,5-tetrazine-
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A series of 3-(benzyl-substituted)-imidazo[5,1-d]-1,2,3,5-tetrazines (13) and related derivatives with 3-
heteromethyl groups has been synthesised and screened for growth-inhibitory activity in vitro against two 
pairs of  glioma cell lines with temozolomide-sensitive and -resistant phenotypes dependent on the 
absence/presence of the DNA repair protein O
6
-methylguanine-DNA methyltransferase (MGMT). In general 
the compounds had low inhibitory activity with GI50 values > 50 µM against both sets of cell lines. Two silicon-
containing derivatives, the TMS-methylimidazotetrazine (9) and the SEM-analogue (10), showed interesting 
differences: compound (9) had a profile very similar to that of temozolomide with the MGMT+ cell lines being 
5 to 10-fold more resistant than MGMT– isogenic partners; the SEM-substituted compound (10) showed 
potency across all cell lines irrespective of their MGMT status. 
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Introduction 
The anticancer drug temozolomide (1, TMZ) was originally synthesised in 1980 and its 
properties were first described in 1984.
1 
The chemical and biological properties of the 
extensive family of anticancer imidazotetrazines have been extensively reviewed over the 
years,
 
most recently in 2014.
2,3
  
TMZ is a small molecule of MW only 194 Da but has a constellation of desirable 
pharmaceutical properties which led to the drug being approved, in combination with 
radiotherapy, for the treatment of glioblastoma multiforme (GBM). Contributing to its 
commercial and clinical success is the benefit of the drug being administered orally in an out-
patients setting. Surprisingly, in the nearly two decades since its marketing launch, no 
mechanistic ‘me-toos’ have entered the market in this niche clinical application. It is the 
ambitious objective of our present research to develop a new agent with the pharmaceutical 
virtues of TMZ, but which overcomes known resistance mechanisms inhibiting its broader 
use. 
It is well established that TMZ is a prodrug that is converted chemically into the triazene 5-
(3-methyltriazen-1-yl)imidazole-4-carboxamide (2: MTIC), which is a precursor of a fugitive 
methylating species, the methyldiazonium ion (3) and 5-aminoimidazole-4-carboxamide (4: 
AIC) (Scheme 1).
4,5 
Methylation of DNA (5) at runs of guanine residues generates inter alia 
6-methoxyguanine-DNA lesions (6) that can be repaired, restoring the integrity of DNA by 
removal of the methyl group by the DNA repair protein O
6
-methylguanine-DNA 
methyltransferase (MGMT): tumours where the MGMT gene is epigenetically silenced 
respond better to the drug than those where the MGMT gene is switched on.
6,7
 Although 
repair of methylated DNA by MGMT represents the major pathway by which tumours derive 
resistance to TMZ, other  mechanisms, both constitutive and acquired, such as mismatch 
repair (MMR) deficiency, further compromise the clinical utility of the drug,
8-10
 and long 
term survival from this most malevolent of diseases is rare. Surprisingly, a case has been 
made recently to propose a wider role for TMZ in the era of precision medicine.
11 
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Scheme 1. Structures of temozolomide (1) and MTIC (2), the formation of O6-methylguanine residues (6) in DNA at runs of 
guanines (G) and repair of methylated DNA by O6-methyl-DNA methyltransferase (MGMT).  
            The versatile Stone synthesis of imidazotetrazines originally employed to synthesise TMZ 
involves the reaction of 5-diazoimidazole-4-carboxamide (7), prepared by nitrosation of AIC 
(4), and an isocyanate and can be exploited to furnish a range of related compounds (Scheme 
2).
1
 We have recently reported on our efforts to identify new imidazotetrazines,
12
 mainly 
prepared by this method, which can introduce novel alkyl lesions into the O-6 position of 
guanine residues in DNA which cannot be repaired by MGMT and are unaffected by the 
MMR status of tumour cells. Of the 50 compounds described, the imidazotetrazine with a 3-
propargyl substituent (8), for example, was equiactive against two sensitive GBM-derived 
cell lines (SNB19V and U373V) and two MGMT-transfected lines (SNB19M and U373M). 
A closer examination of the properties of 8 in a Taq polymerase assay showed that this 
propargyl-imidazotetrazine alkylated plasmid pBR322 DNA at runs of three to five guanines. 
In addition, a piperidine cleavage assay confirmed that 8 covalently modified N-7 sites in 
plasmid DNA in runs of contiguous guanines. These preferential locations are also targeted 
by TMZ.
13
  
Herein we report new investigations on compounds that can be considered as lipophilic 
modifications of the propargyl substituent. These include two silicon-containing 
imidazotetrazines that have had important roles in past synthetic work and are now shown to 
have interesting differences in their activities on GBM cells in vitro, as well as a series of 3-
benzylimidazotetrazines that, in general, have low growth inhibitory activity. 
 
Chemistry 
The TMS-methylimidazotetrazine (9), formed from 7 and TMS-methyl isocyanate has been 
converted into 1 with TBAF and acetic acid in acetonitrile at room temperature in 78% yield 
(Scheme 2),
14
 providing the first practicable route to the prodrug 1 avoiding use of the 
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volatile methyl isocyanate. In an alternative approach the imidazotetrazine (10) formed from 
7 and TMS-ethyloxymethyl isocyanate (SEM isocyanate) could be deprotected by use of 
excess boron trifluoride in chloroform to provide the 3-hydroxymethylimidazotetrazine (11) 
in 95% yield. In turn 11 could be transformed to TMZ (1) with DBU and methyl iodide in 
acetonitrile in a modest 22% yield via an intermediate nor-temozolomide (12) generated in 
situ.
15
 The method has been adopted recently, by others, to synthesise the [
11
C]-methyl 
variant of temozolomide.
16
 The benzyl-imidazotetrazine (13a) has been synthesised 
previously (36%) from 7 and benzyl isocyanate in DMSO
14
 or from nor-temozolomide (12) 
and benzyl alcohol under Mitsunobu conditions (25%).
15
 The syntheses of three other 
imidazotetrazines (13e,
14
 13i,
17
 and 13t
14
) have been reported previously, but the compounds 
were not subjected to pharmacological investigation against the discriminating four cell line 
panel. 
In the present work, reaction of 7 and phenethyl isocyanate afforded the homologue 
(13b) (Scheme 2). Methoxy-substituted benzyl isocyanates were converted into 
imidazotetrazines (13c-13h) in yields that reflect the variable purities of the different 
isocyanates: commercially-available isocyanates of high purity, gave yields of 
imidazotetrazines ranging from 80-90% in the Stone synthesis, whereas less pure isocyanates 
afforded yields of products in the 30-50% range. Attempts to improve the quality of 
isocyanates by vacuum distillation were thwarted by their decomposition under these 
conditions. Isocyanates derived from 5-membered heterocycles, generally prepared by 
Curtius rearrangement of the corresponding acyl azides,
17,18
 were cyclised with 7 to afford the 
series (13i-13m) where the heteromethyl moieties could be considered as benzylic surrogates, 
with the heterocycle offering additional non-covalent bonding opportunities. Synthesis of the 
(1,2,3-triazol-4-yl)methylimidazotetrazine (13n) required a different approach: this was 
prepared (42%) from 8 and TMS-azide in an aqueous t-butanol medium containing sodium 
ascorbate and copper(II) sulfate. Commercially available α-substituted benzyl isocyanates 
were cyclised with 7 to afford the imidazotetrazines (13o-13t) in moderate to good yields. 
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Scheme 2. Synthetic routes to 3-substituted imidazotetrazines. Reagents and Conditions: a) HC≡CCH2NCO, DMSO, 25 °C; 
b) TMSCH2NCO, DMSO, 25 °C; c) TBAF, AcOH, MeCN, 25 °C; d) SEM-NCO, DMSO, 25 °C; e) BF3, CHCl3, 0 °C; f) 
DBU, MeI, MeCN, 25 °C; g) R1R2CHNCO, DMSO, 25 °C) BnOH, PS-PPh3, DIAD, DMF; i) TMS-N3, Na ascorbate, 
Cu(II)SO4, t-BuOH, H2O, 25 °C. 
 
 
On the assumption that the new imidazotetrazines would, like TMZ and 8, act as 
prodrugs and undergo ring-opening to their respective imidazotriazenes 2
1,4
 and 14a,
12
 
respectively, a small series of new triazenes (14b-14g) was prepared by coupling 7 and the 
appropriate amines (Scheme 3) for biological evaluation in comparison with their ring-closed 
counterparts. Yields of triazenes were in the range 75-98%.  
 
Scheme 3. Synthesis of 1-substituted-3-(4-carbamoylimidazol-5-yl)triazenes (14). Reagents and Conditions: a) RCH2NH2, 
EtOAc, 25 °C. 
 
Crystallography 
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The influence of coplanarity of the 8-carboxamide group with the bicyclic nucleus of 
imidazotetrazines in ordering crystal packing has previously been reported for 
mitozolomide
19,20
 The ability of the carboxamide group to make multiple H-bonded 
structures has led to the characterisation of several polymorphs and co-crystals of 
temozolomide.
21
 Similar influences dominate crystal packing in the TMS-
methylimidazotetrazine (9) and its SEM analogue (10) (Figures 1 and 2). In contrast to the 
TMS-derivative (9), the SEM derivative (10) shows intermolecular H-bonding between the 
planes of stacked imidazotetrazines.  These H-bonds arise from an out-of-plane torsion in the 
carboxamide that allows it to access the side-chain SEM oxygen of imidazotetrazines in the 
plane below.  These may account for increased stability in the solid phase, evident as lesser 
water solubility observed qualitatively when handling. 
 
(A) 
 
(B) 
 
Figure 1 (A) X-Ray crystal structure of 3-trimethylsilylmethylimidazotetrazine (9); (B) crystal packing through hydrogen 
bonding. 
 
(A) 
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(B) 
 
Figure 2 (A) X-Ray crystal structure of 3-(2-trimethylsilylethoxy)methylimidazotetrazine (10); (B) crystal packing through 
hydrogen bonding. 
 
1
H NMR spectroscopic studies 
Kinetics experiments observed by 
1
H NMR spectroscopy proved invaluable in identifying 
methyldiazonium ion as an intermediate in the prodrug activation chemistry of TMZ.
4,5
  The 
aqueous chemistry of the new silyl-imidazotetrazines (9) and (10) was investigated by similar 
methods using a neutral phosphate buffer in D2O, pD = 7.0 (equivalent to pH = 7.4).
4
  Data 
for compound 9 are shown in Figure 3 and exhibit significant parallels to TMZ.  In the 
aromatic region, exponential loss of the 6-H signal (δH = 8.67) is accompanied by 
concomitant evolution of the final heterocyclic product of the reaction, AIC (4) 2-H at δH = 
7.34 (for confirmation, see Figure S3, ESI).  The silane region showed a similarly clean 
conversion of the TMS substituent of 9 δH = 0.22) to final product (δH = 0.16) presumed to be 
trimethylsilanol.   
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Figure 3. Reaction of TMS-methylimidazotetrazine (9) in deuterated phosphate buffer.  
 
The signal for the methylene resonance of 9 (δH = 3.99) disappeared exponentially with time 
and the products derived from this part of the starting molecule were very informative.  Two 
products were detected, methanol (δH = 3.36) and methyl phosphate (δH = 3.45), each in 
predominantly deuterated methyl forms (Figure 3, inset); there was no evidence of 
formaldehyde production. The product ratios and deuterium incorporation data were closely 
analogous to those obtained from TMZ (Figure S4, ESI).
4
 Unlike TMZ, however, which 
ultimately transfers an intact methyl group to a nucleophile, any methylation products from 9 
necessarily derive a proton or deuteron from solvent. 
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Scheme 4 Reaction pathways of TMS-methylimidazotetrazine (9) in deuterated phosphate buffer (pD = 7.00). Solid arrows 
indicate a reaction pathway consistent with the NMR spectroscopic data.  Dotted arrows show theoretical alternative routes 
for which no evidence was obtained. 
A reaction pathway consistent with these observations is summarised in Scheme 4, route A.  
The imidazotetrazine undergoes hydrolytic ring-opening to the triazene which fragments to 
the diazonium ion. The diazonium ion loses the TMS group to water to liberate diazomethane 
that is deuterated by solvent to methyl diazonium and methylates a proximal nucleophile. 
There is no evidence to support alternative pathways (B–D) that would involve premature 
hydrolysis of the TMS group as these would necessarily lead to formaldehyde (in the hydrate 
form) as product (ESI).  Whilst the silane group of compound 9 renders it more lipophilic 
than TMZ, the current study implies that in vitro biological responses are likely to be similar 
as they are elicited through similar chemical routes. 
The aqueous behaviour of the SEM-substituted imidazotetrazine (10) was similarly 
investigated (see Figure 4).  The signal-to-noise ratio was determined by the poor water 
solubility of the imidazotetrazine and the need to identify the multiplet structures in the 
aliphatic products.  All of the signals from 10 were clearly visible and clean conversion to the 
products AIC, formaldehyde hydrate and trimethylsilylethanol was evident, (see also Figure 
S5, ESI) without any accumulation of intermediates, Scheme 5, route A, is consistent with 
this result.   
 
 
Figure 4 Reaction of SEM-imidazotetrazine (10) in deuterated phosphate buffer (pD = 7.00).  
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It was notable that product peaks were already evident in the first increment of the kinetic 
run, just a few minutes after initiation of the reaction. Decay of 10 below the detection limit 
of the experiment was complete within 3 h, in contrast to persistence beyond 10 h for the 
TMS derivative (9) (Figure 3) or TMZ.
4,5
 Assignment of the silyl product as 
trimethylsilyethanol was based on the small chemical shift changes in the two multiplets of 
the ethylene unit during reaction.  The second order multiplet structure of the starting 
material was preserved in the products and the methylene adjacent to the silane shifted from 
0.98 to 0.89 ppm. This result shows that reaction of 10 is by hydrolysis of the 
imidazotetrazine and then loss of formaldehyde rather than fragmentation starting at the 
silane terminus of the molecule. There was no evidence of early-stage loss of the SEM group 
(e.g. Scheme 5 routes B, C). This result suggests that 10 would be unlikely to have activity as 
a biological alkylating agent per se.   
 
 
Scheme 5 Proposed reaction pathway for decomposition of the SEM-imidazotetrazine (10).   
 
Biological results and discussion 
Growth inhibitory assays on glioma (GBM) cell lines 
Prior to biological evaluation, all compounds were assessed to have >95% purity by LCMS.
18
 
Compounds were evaluated against four GBM-derived cell lines: two lines sensitive to TMZ 
(SNB19V and U373V) gave GI50 values of 35.7 and 68.0 µM, respectively; two lines 
transfected with MGMT (SNB19M and U373M) showed approximately 13-fold and 5-fold 
resistance to TMZ with GI50 values of 470 and 369 µM, respectively (Table 1). The pattern of 
growth inhibition values for the corresponding ring-opened triazene MTIC (2) is consistent 
with the known prodrug character of TMZ.
4
 and these results are in accord with previously 
published work on these two compounds.
12
 Also we reported
12
 that the 3-propargyl-
imidazotetrazine (8) and its ring-opened triazene derivative (14a) showed growth-inhibitory 
potency superior to TMZ across all four cell lines, confirming that these variants overcome 
the principal resistance mechanism involving expression of MGMT: these results are 
included in Table 1 for comparison purposes.  
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In interpreting the results of tumour cell in vitro growth inhibition assays of the new 
compounds revealed in the present work, it is important to bear in mind that, despite its 
clinical success, TMZ has a very low order of potency against the NCI60 cell panel; typically 
IC50 values are > 100 µM across all cell lines. In keeping with our objective to discover new 
imidazotetrazines active against GBM tumours irrespective of their MGMT status, to warrant 
further interest compounds were required to be approximately equiactive with, or more potent 
than, TMZ against the “V” lines and maintain potency against the “M” lines – i.e. to have a 
‘flat’ activity profile, as exemplified by the marker compound (8). Consequently, new 
compounds with a GI50 value > 50 µM against the temozolomide-sensitive SNB19V cell line 
were, in the absence of other unusual selectivities against the cell panel, de-prioritised and 
their inhibitory activities recorded at the default value (Table 1). As predicted by the NMR 
study, the profile of the TMS-methylimidazotetrazine (9) against the four cell lines is 
strikingly similar in its ‘spikey’ nature to that of TMZ itself (Table 1) with sub 50 µM 
potency only against the SNB19V cell line, and those lines with transfected MGMT (M) 
being approximately 10- and 5-fold resistant to the compound, compared with their vector 
(V) only counterparts. On the other hand the 3-SEM compound (10) showed surprising 
potency against all four cell lines, notably against the more resistant U373 V and M lines. 
The NMR study suggests that this non-selective growth-inhibitory activity may be due to 
liberation of cytotoxic formaldehyde within cells.  
Disappointingly all the 3-benzylimidazotetrazines (13a-13h) showed GI50 values greater than 
the cut-off value and in most cases were only inhibitory in the range 100-200 µM  (data not 
shown). Of the heteromethyl compounds (13i-13n) the (furan-2-yl)methyl derivative (13i) 
was the most inhibitory, but did not achieve the threshold GI50 value, and gave and gave a 
disappointingly featureless profile in the NCI60 screen, reminiscent of TMZ (Figure S6, 
ESI).  Bucking the trend, both enantiomers of the α–methylbenzylimidazotetrazines (13o and 
13p) showed good and equivalent potency against both SNB19V and M lines although they 
were less active against the U373 pair. Other α-substituted benzylimidazotetrazines (13q-t) 
were uninteresting with GI50 values > 50 µM. With the exception of propargyltriazene (14a), 
already mentioned, the series of related triazenes (14b-14g) were deprioritised with GI50 
values in the 100-200 µM range in most cases. Again, the (furan-2-yl)methyltriazene (14d), 
the ring-opened counterpart of imidazotetrazine (13i), was the most active albeit exceeding 
the required threshold GI50 value of < 50 µM. 
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Table 1 In vitro growth inhibitory activities of 3-substituted imidazotetrazines and related triazenes against human-derived 
glioblastoma cell lines a 
 Mean GI50 (µM) 
b 
Compound (s) SNB19V SNB19M U373V U373M 
1, TMZ 35.7 ± 12 470 ± 88.7 68.0 ± 32 369 ± 86.1 
2 48.5 ± 17.9 472 ± 88.7 93.7 ± 39.7 398 ± 33.7 
8 35.6 ± 14.2 37.8 ± 11.7 37.6 ± 11.4 36.1 ± 9.6 
9 28.4 ± 5.9 302 ± 69.5 45.6 ± 14.5 249.5 ± 72.1 
10 29.9 ± 5.3 27.5 ± 1.4 25.3 ± 3.0 24.2 ± 2.7 
13a-13n >50 >50 >50 >50 
13o 32.7 ± 1.3 49.7 ± 5.2 >50 >50 
13p 34.7 ± 0.8 45.3 ± 6.0 >50 >50 
13q-13t >50 >50 >50 >50 
14a 39.1 ± 5.3 33.9 ± 1.5 32.0 ± 6.9 35.6 ± 1.2 
14b-14g >50 >50 >50 >50 
a Glioma lines: SNB19V and U373V (vector transfection only, MGMT activity 4 and 56 fmol/mg MGMT, respectively); 
SNB19M and U373M (stable MGMT transfection 649 and 648 fmol/mg, respectively). b GI50 values were determined by a 
7-day MTT assay and where GI50 values are < 50 µM are shown as the mean ±SD of ≥ 3 independent experiments (n=4-8 
per experiment). All compounds were dissolved in DMSO at stock concentration 100 mM, stored at –20 °C and diluted in 
culture medium immediately prior to use.  
 
 
Conclusions 
The 3-benzylimidazotetrazine series does not reveal useful inhibitory activity against the 
glioblastoma cell panel or a characteristic profile like the methyl analogue TMZ notable for 
enhanced activity against the V cell lines and resistance towards the MGMT-expressing M 
lines.
12
 A possible reason for this observation could be a chemical inability of the compounds 
(or their ring-opened forms) to transfer a benzyl fragment to DNA or, alternatively, that an 
O
6
-benzylguanine intrusion, if indeed formed,  is not perceived to be a cytotoxic lesion by the 
cell. NMR Spectroscopic investigation (Figures S7, 8, ESI) implied that there may be more 
than one pathway for reaction of derivative 13a in phosphate buffer and showed that benzyl 
group transfer to solvent (benzyl alcohol) was not the major reaction product. Moreover, 
investigation of tautomerism in the triazene showed that the tautomer present in DMSO 
solution was not that from which a diazonium ion could be released (Figure S9, ESI). The 
failure to generate O
6
-benzylguanine-DNA seems the likely reason for inactivity as it is 
known that O
6
-benzylguanine is a substrate for MGMT, and had DNA benzylation occurred, 
it should have been reflected in activity against MGMT–  cell lines.
22
 Despite its overall 
potency against the four cell line panel, the SEM-substituted imidazotetrazine (10), which 
outperforms that of the lead propargylimidazotetrazine (8) as reported in the present work, 
has pharmaceutical liabilities in terms of stability and potential vulnerability to metabolic 
degradation. The NMR study confirms that this compound does not fragment by a TMZ-like 
alkylation mechanism. Tentatively we suggest that its overall inhibitory properties may be 
explained by its liberating cytotoxic formaldehyde within cells.  
In future publications we will report on the extensive series of compounds we have 
synthesised and evaluated with a propargyl substituent at N-3 and modifications of the 8-
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carboxamide group in an effort to select a candidate which overcomes known mechanisms by 
which GBM tumours mount resistance towards the prototype compound TMZ. Additionally, 
by fine-tuning the pharmaceutical properties of future drug candidates by varying the nature 
of the substituent at C-8, we are seeking to identify a new agent for a proof-of-principle in 
vivo evaluation in a mouse xenograft model implanted with GBM tumours sensitive and 
resistant to TMZ. 
Experimental section 
Chemistry 
Most imidazotetrazines and all imidazotriazenes decomposed in their melting ranges which 
varied according to the rate of heating. Melting points were not a reliable means to assess 
purity. Compounds were purified by crystallisation or flash chromatography on Merck silica 
gel 60. Compounds 9,
14
 10,
14
 13a,
14 
13e,
1
 13i 
17 
and 13t
14
 have been reported previously.  
General method for the synthesis of 3-substituted imidazotetrazines (13) 
To a stirred suspension of 4-diazoimidazole-5-carboxamide (7) (0.5 g, 3.65 mmol) in dry 
DMSO (5 mL) was added dropwise a substituted isocyanate (4.2 mmol) at 25 °C under 
nitrogen. After 24 h the mixture was poured into ice and the imidazotetrazine extracted in 
DCM (3 × 25 mL). The organic fraction was washed with water, dried (Na2SO4) and solvent 
removed by vacuum evaporation. The product was triturated with EtOAc, collected by 
filtration and dried in vacuo at 25 °C. A selected example was the 3-benzylimidazotetrazine 
13a, formed from 7 and benzyl isocyanate, isolated as a grey solid (48%), m.p. 188 °C 
(decomp.) with physical characteristics (IR, 
1
H and 
13
C NMR) identical to an authentic 
sample.
14
 
General method for the synthesis of imidazotriazenes (14) 
A mixture of 4-diazoimidazo-5-carboxamide (7) and an amine (1 mol. equiv.) was stirred at 
25 °C for 4 h in dry EtOAc. Products 14 a-g were collected and washed with dry EtOAc.  
(Note: imidazotriazenes are unstable in polar solvents and were stored at 0–4 °C. Their 
melting points vary according to the rate of heating and are often accompanied by vigorous 
effervescence.)  If pure when analysed by highfield NMR, compounds were used in 
biological evaluations without further purification. 
 
Experimental details and characterization data for imidazotetrazines 13 and imidazotriazenes 
14 are given in the ESI. 
 
Crystallography 
Details of X-ray crystallography are given in the ESI. 
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NMR Kinetics 
1
H NMR kinetic experiments were performed on a Jeol ECA600 instrument observing 
1
H at 
600.1723 MHz. Data were processed using Delta NMR software (5.0.5, Jeol Resonance Ltd). 
Phosphate buffer (200 mM in D2O) was prepared by mixing solutions of NaH2PO4 (0.138 g 
in 5 mL D2O) and Na2HPO4 (0.178 g in 5 mL D2O) with monitoring by a recently calibrated 
pH meter until a reading of pD=7.000 was obtained. Imidazotetrazines were dissolved in d6-
DMSO (10 mM). 
In a typical NMR experiment, buffer (0.7 mL) was placed in an NMR tube, equilibrated at 37 
°C in the probe for 10 min and the magnet shimmed. The tube was ejected, imidazotetrazine 
stock (200 µL) added, mixed thoroughly and returned to the spectrometer. Shims were 
adjusted and spectra recorded every 15 min for 12–18 h. Spectra were acquired with 64 
transients, sweep width 15 ppm and digitised to 65 K data points. The residual H2O/HOD 
peak was presaturated during the relaxation delay (5 s). Data were zero-filled once and an 
exponential window function (0.3–1.0 Hz) was applied during Fourier transformation. 
Artefacts due to water suppression were removed digitally. At the end of reaction, a further 
high resolution spectrum was acquired and peaks identified by spiking with small samples of 
authentic materials (AIC, HCHO, Figures S3, S5, ESI). 
 
Anti-proliferative assays 
HCT 116 cells were purchased from the American Type Tissue collection 
 
Stock solutions of TMZ and other compounds listed in Table 1 were prepared in DMSO (100 
mM) and aliquots stored at –20 °C, protected from light. SNB19V, SNB19M, U373V and 
U373M were originally obtained from Schering-Plough Research Institute, USA and were 
verified as being mycoplasma free. Cells were maintained in RPMI 1640 nutrient medium 
supplemented with 10% foetal bovine serum (FBS), sub-cultivated twice weekly and 
incubated at 37 °C in an atmosphere containing 5% CO2. 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were performed 
as reported previously.
8,9
 Compound concentration required to inhibit 50% growth (GI50 / 
µM) were calculated using non-linear regression analysis. 
 
Conflicts of interest 
DC, MGH, JZ and HSS were former employees of Pharminox Ltd; TDB and MFGS were consultants 
to, and MFGS a shareholder of, Pharminox Ltd. 
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